Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

A study conducted bà Cattolica in Rome and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has uncovered a ...

FDA reported that, for now, companies can continue to market OTC monograph drug products containing oral phenylephrine as a ...

About 300 million people suffer from depression worldwide, according to the World Health Organization The US drugs regulator has approved the sale of a new nasal spray to treat depression.

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...

The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended ...

"It has been linked to a variety of medical conditions including cardiovascular disease, stroke, obesity, diabetes, anxiety ...

May give additional doses (using a new nasal spray) every 2–3mins in alternate nostrils if unresponsive or relapses into respiratory depression. Not a substitute for emergency medical care.

A study testing a new nasal spray form of the medication bumetanide, a commonly prescribed diuretic, was found to be as safe and well-tolerated (meaning with no significant nasal irritation ...

COLLEGE STATION, Texas — November is National Alzheimer's Awareness Month and now a new therapy out of Texas A&M University could treat Alzheimer's disease through a nasal spray. Seven million ...